William Blair downgraded Mersana Therapeutics (MRSN) to Market Perform from Outperform after the company announced an agreement to be acquired by Day One Biopharmaceuticals (DAWN) for $25 per share in cash along with a milestone-based contingent value right worth up to $30.25 per share in total. The firm views it as unlikely that another bidder will emerge, the analyst tells investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRSN:
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- Mersana Therapeutics downgraded to Neutral from Buy at Guggenheim
- Mersana downgraded to Market Perform from Outperform at LifeSci Capital
- Hold Rating on DAWN’s Acquisition of Mersana Therapeutics: Balancing Opportunities and Risks Amid ACC Focus
- Hold Rating on Mersana Therapeutics Acquisition by Day One Biopharmaceuticals: Strategic Alignment and Risk-Adjusted Valuation